BLAINJECTIONINJECTABLEPriority Review
Approved
Jan 2023
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
10
Data completeness
7/8 — Comprehensive
Priority Review
LEQEMBI (lecanemab) by Eisai is amyloid beta-directed antibody interactions [moa]. Approved for amyloid beta-directed antibody [epc]. First approved in 2023.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEQEMBI (lecanemab) is a monoclonal antibody that targets amyloid beta, a key pathological hallmark of Alzheimer's disease. It is indicated for mild cognitive impairment and mild dementia stages of Alzheimer's disease, including preclinical and familial variants. The drug works by binding to amyloid beta protofibrils, slowing cognitive decline in early-stage disease.
$0.017BPart D
PeakProduct is at peak lifecycle stage post-launch (Jan 2023), indicating stable commercial operations and established market presence with moderate team staffing needs.
Mechanism of Action
Amyloid Beta-directed Antibody Interactions
Pharmacologic Class:
Amyloid Beta-directed Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (10)
The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab.
Started Dec 2025
60 enrolled
Alzheimers Disease
A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease
Started Feb 2025
3,000 enrolled
Alzheimer's Disease
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
Started Sep 2024
105 enrolled
Alzheimer's Disease
Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease
Started Apr 2024
200 enrolled
Mild Cognitive ImpairmentAlzheimer Disease
A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
Started Feb 2024
5,000 enrolled
Alzheimer's Disease
Worked on LEQEMBI at Eisai? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.